Drug Trial Radar · NCT04570332
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Dec 30, 2020
Primary completion
Oct 3, 2023
Study completion Nov 4, 2024
Sponsor
- Lead sponsor
- Highlight TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Sep 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab. The study will enroll patients with advanced and/or metastatic melanoma that have progressed on anti-PD-1-containing treatment.
Conditions
- Melanoma
Interventions
BO-112 plus pembrolizumabDrug
Patients will be treated with the combination of BO-112 and pembrolizumab. Order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles
Tissue BiopsiesProcedure
Pre and post (if feasible) treatment tumor tissue biopsies will be used for correlative research.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: From the first dose of study treatment to the date of CR or PR assessed up to 2 years
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
Centre Hospitalier Universitaire de Grenoble
Grenoble, France
Hopital Lyon Sud
Lyon, France
Centre Hospitalier Universitaire de Nantes
Nantes, France
Centre Hospitalier Universitaire de Nice
Nice, France
Hôpital Ambroise-Paré
Paris, France
Institut Gustave Roussy
Paris, France
H. Universitari Quirón Dexeus
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Clara Campal - HM Sanchinarro
Madrid, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
MD Anderson Cancer Center
Madrid, Spain
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain
Clínica Universidad de Navarra
Pamplona, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
H. General Universitario de Valencia
Valencia, Spain
H. Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.